Roles of miR-944 and MARCH7 mRNA in prognosis assessment of non-small cell lung cancer patients

doi:10.3969/j.issn.1673-8640.2025.12.004

Abstract

Abstract:

Objective To investigate the relationship between the expression of miR-944 and membrane-associated ring finger protein 7（MARCH7） mRNA in cancer tissues of non-small cell lung cancer（NSCLC） patients and their clinical pathological characteristics and prognosis. Methods A total of 97 NSCLC patients from Liyang People's Hospital from July 2019 to July 2020 were enrolled. All patients' clinical data were collected，and cancer tissues and adjacent tissues（≥2 cm from tumor margin） were collected during surgery. The relative expression levels of miR-944 and MARCH7 mRNA were determined. All the patients were followed up for 3 years. The survival of all the patients was analyzed using Kaplan-Meier survival curve. Cox regression analysis was used to evaluate the factors affecting the prognosis of NSCLC patients. Results The relative expression levels of miR-944 and MARCH7 mRNA in cancer tissues of NSCLC patients were higher than those in adjacent tissues（P<0.05）. The relative expression levels of miR-944 and MARCH7 mRNA in NSCLC patients with TNM stage Ⅲa，lymphatic metastasis and low differentiation were higher than those in NSCLC patients with TNM stage Ⅰ-Ⅱ，no lymphatic metastasis and moderate to high differentiation（P<0.05）. The optimal cut-off values of miR-944 and MARCH7 mRNA in cancer tissues for predicting NSCLC patient death were 2.39 and 3.05，respectively. NSCLC patients were classified into miR-944 and MARCH7 mRNA high-expression and low-expression groups based on the optimal cut-off values. The 3-year overall survival rate of miR-944 high-expression group [27.03%（10/37）] was lower than that of miR-944 low-expression group [48.15%（26/54）]（Log-rank χ²=5.901，P=0.015）. The 3-year overall survival rate of MARCH7 mRNA high-expression group [28.13%（9/32）] was lower than that of MARCH7 mRNA low-expression group [45.76%（27/59）]（Log-rank χ²=9.998，P=0.002）. Lymphatic metastasis，TNM stage Ⅲa，low differentiation，high miR-944 expression and high MARCH7 mRNA expression were risk factors for NSCLC patient death（P<0.05）. Conclusions The miR-944 and MARCH7 mRNA are highly expressed in NSCLC cancer tissues and are related to the severity of disease and prognosis. They may be used as indicators for prognosis assessment in NSCLC patients.

Key words: MicroRNA-944, Membrance-associated ring finger protein 7, Non-small cell lung cancer, Clinical pathological characteristic, Prognosis

CLC Number:

R446.1

HUANG Ting, XU Yan, SHI Qingxing, PENG Ying. Roles of miR-944 and MARCH7 mRNA in prognosis assessment of non-small cell lung cancer patients[J]. Laboratory Medicine, 2025, 40(12): 1159-1164.

Figures/Tables 7

References 26

[1]	赵健, 刘利群, 艾飞玲, 等. 中国2013—2018年≥30岁居民肺癌死亡率变化轨迹分析[J]. 中国公共卫生, 2021, 37(10):1495-1500.
[2]	邓正亭, 赵凡, 赵彤, 等. 基于数据挖掘技术探析中医药治疗中晚期非小细胞肺癌的用药规律[J]. 中国实验方剂学杂志, 2022, 28(3):171-179.
[3]	谭晓刚, 支修益. MicroRNA与非小细胞肺癌[J]. 首都医科大学学报, 2015,4:519-524.
[4]	郭凤, 黄伟, 王佩红, 等. miR-944在HPV16阳性宫颈癌患者组织表达及临床意义[J]. 中国妇幼健康研究, 2023, 34(3):94-98.
[5]	李新菊, 宋宇, 王学玲. miR-944靶向调控S100PBP基因促进宫颈癌细胞迁移和侵袭的机制探讨[J]. 现代肿瘤医学, 2019, 27(7):1122-1127.
[6]	LIU M, ZHOU K, CAO Y. MicroRNA-944 affects cell growth by targeting EPHA7 in non-small cell lung cancer[J]. Int J Mol Sci, 2016, 17(10):1493. DOI URL
[7]	胡建国. MARCH7促进上皮性卵巢癌恶性进展及机制的研究[D]. 重庆: 重庆医科大学, 2016.
[8]	SINGH S, BANO A, SARAYA A, et al. Association of MARCH7 with tumor progression and T-cell infiltration in esophageal cancer[J]. Med Oncol, 2022, 40(1):67. DOI PMID
[9]	鲁小敏. MARCH7在非小细胞肺癌中的作用及其机制研究[D]. 苏州: 苏州大学, 2021.
[10]	赵泽坤, 周志明, 王建雄, 等. 影像学检查指标、血清肿瘤标志物、细胞分子标志物在ICC淋巴结转移预测中的应用进展[J]. 山东医药, 2023, 63(12):92-95.
[11]	张嘉文, 申婷, 李海鹏, 等. 循环外泌体miR-17-5p和miR-21-5p检测在NSCLC早期诊断及进展评估中的价值[J]. 河北医药, 2022, 44(13):1978-1981.
[12]	周潇, 邹强, 张岩. 7项肿瘤相关抗原自身抗体在不同分期非小细胞肺癌诊断中临床意义[J]. 临床军医杂志, 2022, 50(9):922-925.
[13]	HE H, TIAN W, CHEN H, et al. MiR-944 functions as a novel oncogene and regulates the chemoresistance in breast cancer[J]. Tumour Biol, 2016, 37(2):1599-1607. DOI URL
[14]	PARK S, KIM J, EOM K, et al. MicroRNA-944 overexpression is a biomarker for poor prognosis of advanced cervical cancer[J]. BMC Cancer, 2019, 19(1):419. DOI PMID
[15]	张田, 任丹, 李杰. circBIRC6通过miR-944/CD44轴促进PD-L1介导的非小细胞肺癌免疫逃逸[J]. 河北医学, 2022, 28(12):1969-1977.
[16]	熊飞, 詹瑧, 唐于平, 等. PI3K/Akt信号转导通路在非小细胞肺癌中的作用[J]. 中国药理学通报, 2010, 26(10):1264-1267.
[17]	BARARTABAR Z, MOINI N, ABBASALIPOURKABIR R, et al. Investigation of miR-133a,miR-637 and miR-944 genes expression and their relationship with PI3K/AKT signaling in women with breast cancer[J]. J Cancer Res Clin Oncol, 2023, 149(9):6115-6129. DOI
[18]	王暖, 杨丽娟, 刘成霞. 膜相关环状蛋白在肿瘤中作用的研究进展[J]. 山东医药, 2021, 61(2):84-87.
[19]	王暖, 杨丽娟, 刘成霞. MARCH1在免疫及肿瘤等方面的研究进展[J]. 国际医药卫生导报, 2021, 27(11):1582-1587.
[20]	王美姣. MARCH家族蛋白在免疫、生殖等方面的研究进展[J]. 重庆医学, 2016, 45(29):4144-4147.
[21]	刘玲. MARCH7调控子宫内膜癌恶性进展的作用与机制研究[D]. 重庆: 重庆医科大学, 2017.
[22]	刘红梅, 王志鹏, 刘志刚. 党参总皂苷通过调控miR-142-3p/MARCH7轴影响乳腺癌细胞MCF-7增殖和凋亡[J]. 毒理学杂志, 2021, 35(6):465-469.
[23]	CHEN T, MENG Y, ZHOU Z, et al. GAS5 protects against nonalcoholic fatty liver disease via miR-28a-5p/MARCH7/NLRP3 axis-mediated pyroptosis[J]. Cell Death Differ, 2023, 30(7):1829-1848. DOI PMID
[24]	ZHANG L, WANG H, TIAN L, et al. Expression of USP7 and MARCH7 is correlated with poor prognosis in epithelial ovarian cancer[J]. Tohoku J Exp Med, 2016, 239(3):165-175. DOI PMID
[25]	HU J, ZHANG L, MEI Z, et al. Interaction of E3 Ubiquitin ligase MARCH7 with long noncoding RNA MALAT1 and autophagy-related protein ATG7 promotes autophagy and invasion in ovarian cancer[J]. Cell Physiol Biochem, 2018, 47(2):654-666. DOI PMID
[26]	李祺瑞, 陈美娟. 细胞自噬与非小细胞肺癌关系的研究进展[J]. 中国肿瘤, 2022, 31(5):380-386.

基因名称	上游引物（5'~3'）	下游引物（5'~3'）
miR-944	CCTGTGCTGCGAAGTGGAAAC	TTCGATCTGCTCCTGGCAGG
U6	ACCTGGGCTACGGGTTACTTAT	ATTCGGTGCGACTGATCCGT
MARCH7	TGTGTGGAGAGCGTCAACCG	TGGATCCAGGTGTGCAGGT
β-actin	ACTGCTGCTGGTCACCTAACT	ACTCCTACTGCCTGACTATC

基因名称	上游引物（5'~3'）	下游引物（5'~3'）
miR-944	CCTGTGCTGCGAAGTGGAAAC	TTCGATCTGCTCCTGGCAGG
U6	ACCTGGGCTACGGGTTACTTAT	ATTCGGTGCGACTGATCCGT
MARCH7	TGTGTGGAGAGCGTCAACCG	TGGATCCAGGTGTGCAGGT
β-actin	ACTGCTGCTGGTCACCTAACT	ACTCCTACTGCCTGACTATC

组织	例数	miR-944	MARCH7 mRNA
癌旁组织	97	0.93±0.24	0.68±0.16
癌组织	97	2.45±0.61	3.18±0.77
t值		22.837	31.308
P值		<0.001	<0.001

组织	例数	miR-944	MARCH7 mRNA
癌旁组织	97	0.93±0.24	0.68±0.16
癌组织	97	2.45±0.61	3.18±0.77
t值		22.837	31.308
P值		<0.001	<0.001

临床病理特征	例数	miR-944	MARCH7 mRNA	临床病理特征	例数	miR-944	MARCH7 mRNA
年龄				吸烟史
<60岁	29	2.42±0.60	3.16±0.77	无	44	2.36±0.55	3.12±0.69
≥60岁	68	2.47±0.59	3.22±0.80	有	53	2.53±0.62	3.23±0.72
t值		0.380	0.341	t值		1.414	0.763
P值		0.704	0.733	P值		0.161	0.447
性别				组织分化程度
女	34	2.38±0.57	3.13±0.72	中高分化	41	2.31±0.47	3.01±0.57
男	63	2.51±0.62	3.25±0.73	低分化	56	2.67±0.65	3.42±0.85
t值		1.012	0.776	t值		3.165	2.841
P值		0.314	0.439	P值		0.002	0.005
肿瘤直径				淋巴转移
<3 cm	27	2.40±0.58	3.15±0.78	无	39	2.27±0.45	2.95±0.60
≥3 cm	70	2.49±0.61	3.21±0.80	有	58	2.69±0.64	3.45±0.82
t值		0.660	0.333	t值		3.794	3.465
P值		0.511	0.739	P值		0.001	0.001
病理类型				TNM分期
鳞癌	34	2.39±0.57	3.14±0.75	Ⅰ+Ⅱ期	44	2.32±0.48	3.05±0.54
腺癌	63	2.48±0.56	3.24±0.73	Ⅲa期	53	2.71±0.62	3.39±0.81
t值		0.751	0.637	t值		3.408	2.466
P值		0.454	0.525	P值		0.001	0.014